Fenwick Represents Freenome in $254M Financing

Fenwick represented Freenome, a biotechnology company developing blood tests for early cancer detection, in its additional $254 million financing. The round was led by Roche, with participation from a16z Life Sciences Growth Fund, the American Cancer Society’s BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics (NYSE: DGX), RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, with funds and accounts advised by T. Rowe Price Associates, Inc. and others.

Freenome will use the funds to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform. More information can be obtained from the company’s announcement.

The transaction was led by corporate partners Michael Esquivel and Patrick Grilli and included associates Myles Gutenkunst, Rich Minice, Sloka Tankala, Brandon Ho and Ryan Kidman.